Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is one of the best robotic surgery stocks to buy.
Canaccord cut the price target on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to $83 from $93 on April 29, and maintained a Buy rating on the shares
The firm stated that the company delivered a solid fiscal Q1 to start the year, and as it relates to its US go-to-market transformation, the company called out modest disruption in Q1 within expectations as it continued to execute the changes. This occurred with specialization increasing to ~30% of the force, non-dedicated reps declining to below 60%, and early productivity gains in transitioned territories. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) also received a rating update from Citizens on April 29.
The firm cut the price target on the stock to $105 from $120, maintaining an Outperform rating on the shares. The firm stated that the company delivered stronger EPS outperformance in fiscal Q1 and a modest revenue beat, which was largely driven by tariff-related benefits boosting margins. It further told investors in a research note that although core performance was mixed, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) raised its EPS guidance and maintained its revenue outlook to reflect tariff impacts.